Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.57 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.57 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.57 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.57 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.57 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.57 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.57 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.57 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.57 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.57 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.57 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 5/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151218 | 0.98 | NFKB1 (0.71) | BLMPMP22NFKB1MAPTTDP1 | |
| SCHEMBL249737 | 0.98 | NFKB1 (0.71) | BLMPMP22NFKB1MAPTTDP1 | |
| SCHEMBL7149100 | 0.86 | BLM (0.59) | BLMPMP22NFKB1MAPTTDP1 | |
| SCHEMBL7143077 | 0.85 | NFKB1 (0.57) | BLMPMP22NFKB1MAPTTDP1 | |
| SCHEMBL3216247 | 0.85 | NFKB1 (0.66) | BLMPMP22NFKB1MAPTTDP1 | |
| Normetanephrine SCHEMBL1168235 | 0.84 | BLM (1.00) | BLMPMP22NFKB1MAPTTDP1 | |
| SCHEMBL18652057 | 0.83 | CYP3A4 (0.51) | BLMPMP22NFKB1MAPTCYP3A4 | |
| SCHEMBL18328542 | 0.83 | CYP3A4 (0.51) | BLMPMP22NFKB1MAPTCYP3A4 | |
| Normetanephrine SCHEMBL4949341 | 0.82 | NFKB1 (1.00) | BLMPMP22NFKB1MAPTTDP1 | |
| Normetanephrine SCHEMBL29516838 | 0.82 | NFKB1 (1.00) | BLMPMP22NFKB1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1707 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345897-A1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2018-07-11 | — | — | EP | claimed |
| US-10011584-B2 | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2018-07-03 | — | — | US | claimed |
| US-9951042-B2 | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl] pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2018-04-24 | — | — | US | claimed |
| EP-2697215-B1 | AMORPHOUS (5-FLUORO-2-METHYL-3-QUINOLIN-2-YLMETHYL-INDOL-1-YL)-ACETIC ACID | ATOPIX THERAPEUTICS LTD (GB) | 2017-11-22 | — | — | EP | claimed |
| US-20170121306-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | SOLVIAS AG (CH) | 2017-05-04 | — | — | US | claimed |
| EP-3137452-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2017-03-08 | — | — | EP | claimed |
| EP-3137453-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | Atopix Therapeutics Limited (GB) | 2017-03-08 | — | — | EP | claimed |
| US-20170057944-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | SOLVIAS AG (CH) | 2017-03-02 | — | — | US | claimed |
| WO-2015166278-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-11-05 | — | — | WO | claimed |
| WO-2015166280-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL] PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-11-05 | — | — | WO | claimed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | claimed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | claimed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | claimed |
| WO-2002051814-A1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2002-07-04 | — | — | WO | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011584-B2 | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid | CYP1B1, CYP3A5, CYP1A1 | ADRB3 77/4885ADRB2 137/4885ADRB1 69/4885 |
| US-20170121306-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | UGT1A1, CYP3A5, CYP2D6 | ADRB3 144/4885ADRB2 221/4885ADRB1 132/4885 |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | ADRB3 16/4885ADRB2 37/4885ADRB1 33/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | ADRB3 72/4885ADRB2 249/4885ADRB1 191/4885 |
| US-20170057944-A1 | POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID | CYP3A5, CYP1B1, CYP1A1 | ADRB3 85/4885ADRB2 125/4885ADRB1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.